How BAF/PBAF chromatin-remodeler mutations predict better checkpoint-inhibitor outcomes — and point toward combination strategies
Anti-angiogenic therapy combination with hypoxia-regulating agent leads to improved tumor regression in a murine model of renal carcinoma
Background While antiangiogenic therapies have been shown effective in preclinical and clinical trials, tumors can acquire resistance conferring them the ability to survive and grow under hypoxic conditions, even, induced by antiangiogenic drugs themselves. Methods This study investigated the effects of an antiangiogenic strategy and hypoxia-regulating agent, each alone and in combination. Here, we have […]